Hyponatremia Correction: 5 Critical Practice Considerations

Why Hyponatremia Correction Matters

Hyponatremia, a serum sodium below 135 mmol/L, is the most common electrolyte disturbance in hospital practice. It is present in roughly 14% to 42% of admitted patients, and a lower sodium level is consistently associated with higher mortality across clinical settings.

What makes treatment uniquely hazardous is the brain’s own adaptation. In chronic hyponatremia, neurons and glia extrude organic osmolytes to avoid swelling in a dilute environment. Raising the sodium too quickly then pulls water out of these solute-depleted cells and injures myelin.

The result is osmotic demyelination syndrome, which comprises central pontine and extrapontine myelinolysis. It can cause dysarthria, dysphagia, spastic quadriparesis, and a locked-in state, often after a deceptive lucid interval of several days.

So the same intervention that relieves life-threatening cerebral edema can, if it overshoots, cause irreversible neurologic injury. That double-edged quality is why the rate of correction — not simply reaching a normal sodium — is the central safety question.

The Clinical Problem in Hyponatremia Correction

The therapeutic window is narrow and asymmetric. Acute symptomatic hyponatremia with seizures or coma needs prompt partial correction — raising sodium about 4 to 6 mmol/L relieves the immediate risk of herniation — yet the total 24-hour rise must stay bounded to avoid demyelination.

Overcorrection is common rather than exceptional. In a retrospective cohort of 1,490 patients with serum sodium below 120 mEq/L, rapid correction (a rise greater than 8 mEq/L at 24 hours) occurred in 41%, with a median 24-hour change of 6.8 mEq/L. Nearly every patient who developed demyelination had a documented episode of rapid correction.

The usual driver of overshoot is a sudden water diuresis. Once the stimulus for antidiuretic hormone is removed — through volume repletion, cortisol replacement, stopping a thiazide, or correcting hypokalemia — the kidney abruptly excretes free water, and sodium climbs faster than intended.

Certain features concentrate the danger. The highest ODS risk is seen with a very low starting sodium, chronic (more than 48-hour) hyponatremia, alcohol use disorder, malnutrition, advanced liver disease, and hypokalemia. Identifying these patients up front shapes how cautiously correction should proceed.

Available Approaches

Three levers control the risk: how high the sodium is allowed to rise (the limit), how hypertonic saline is delivered, and how the correction is actively braked with desmopressin. The comparative evidence for each is summarized below, followed by a closer look at all three.

Setting and monitoring the correction rate limit

United States expert-panel recommendations cap the 24-hour rise at 8 mEq/L in high-risk patients — those with a sodium at or below 105 mEq/L, hypokalemia, alcoholism, malnutrition, or advanced liver disease — and at 10 to 12 mEq/L in others with chronic severe hyponatremia.

The European guideline sets a 10 mmol/L ceiling in the first 24 hours and a further 8 mmol/L per 24 hours until the sodium exceeds 130 mmol/L. Both frameworks rest largely on expert opinion and observational data rather than randomized evidence.

Frequent monitoring anchors the whole approach. Checking serum sodium every 2 to 6 hours during active correction allows the rate to be caught and slowed before the ceiling is crossed, because the slope can accelerate unpredictably once diuresis begins.

Delivering hypertonic saline — bolus versus infusion

Current guidelines favor small fixed boluses of 3% saline — about 100 to 150 mL over 10 to 20 minutes — to raise sodium 4 to 6 mmol/L promptly in symptomatic patients, repeated as needed rather than run as an open-ended drip.

The SALSA randomized trial enrolled 178 patients with symptomatic sodium at or below 125 mmol/L and compared rapid intermittent bolus with slow continuous infusion. Overcorrection (a rise above 12 mmol/L at 24 hours or 18 mmol/L at 48 hours) occurred in 17.2% with bolus versus 24.2% with infusion — a nonsignificant difference (absolute risk difference −6.9%, 95% CI −18.8% to 4.9%). No patient in either arm developed ODS.

Bolus dosing required fewer therapeutic re-lowering interventions than infusion (41.4% versus 57.1%; absolute difference −15.8%, 95% CI −30.3% to −1.3%; number needed to treat 6.3) and reached the one-hour target more often. It is also simpler because it needs no formula, and it was suggested as the preferred approach.

Desmopressin to prevent and reverse overcorrection

Because overcorrection is driven by unexpected water diuresis, desmopressin is used to clamp free-water excretion and hold the rate steady. Three strategies are described: proactive dosing at the outset in high-risk patients alongside 3% saline, reactive dosing when brisk aquaresis appears, and rescue dosing after the limit is already breached.

A 2024 randomized trial in 49 patients with symptomatic sodium below 125 mmol/L compared proactive with reactive desmopressin. Overcorrection did not differ significantly between them (16.7% versus 28%), though the small sample limits precision. Both kept the 48-hour sodium change within a safe range, and no ODS occurred.

When the ceiling is crossed, re-lowering the sodium with 5% dextrose, with or without desmopressin, can bring it back into the target range. This rescue step is a routine part of protocols that monitor sodium frequently enough to detect the overshoot.

Comparative Analysis

Read together, the evidence tells two stories that are in genuine tension. The historical, guideline-anchored view holds that rapid correction raises ODS risk, so limits protect patients. It is supported by cohorts such as George and colleagues and by two meta-analyses, in which rapid correction was associated with higher ODS (OR 3.16, 95% CI 1.54–6.49; and RR 3.91, 95% CI 1.17–13.04).

A newer body of work argues the limits may be too conservative. In a multicenter cohort of hospitalized patients, demyelination was very rare (0.05%) and was not associated with correction rate. A separate two-hospital cohort of 3,274 patients found correction slower than 6 mmol/L per 24 hours associated with higher in-hospital mortality, and correction faster than 10 mmol/L associated with lower mortality.

A 2025 meta-analysis of 16 cohorts and 11,811 patients similarly linked slow and very slow correction to higher mortality, without an increase in ODS. Its authors estimated meaningfully fewer in-hospital deaths with faster correction.

The reconciling point is study design. These mortality signals come almost entirely from observational data, so residual confounding is the central caveat: sicker patients tend to have both lower sodium and higher mortality, which can make slow correction appear harmful. A large expert panel has argued that the guidelines should stand, particularly for high-risk patients. The result is that the numeric ceiling is settled in guidelines but actively contested in the recent literature.

Quality and Consistency of the Evidence

The certainty attached to each question varies, and separating them prevents the strength of one conclusion from being borrowed by another.

• Hyponatremia’s association with mortality — strong and consistent across multiple large cohorts, though this reflects association rather than a proven causal effect.
• Bolus versus infusion delivery — moderate, resting on one randomized trial (SALSA) with a consistent direction of effect but a wide confidence interval.
• Rapid correction and ODS risk — moderate; several cohorts and two meta-analyses agree on the direction, but events are rare and the definition of “rapid” varies between studies.
• Slow correction and mortality — low to moderate; consistent across recent observational studies but confounded by illness severity, with no randomized trial.
• Desmopressin strategy — low; a single small randomized trial plus observational series, underpowered to detect meaningful differences in ODS.
• The correction limits themselves — widely adopted as consensus, but the underlying evidence is largely expert opinion and observational data.

What the Evidence Does Not Show

Practical Implications

The evidence supports a structured, individualized approach rather than a single rigid rule. Five considerations follow from the data.

1. Set the target and ceiling before starting, stratified by ODS risk. Plan for the tighter limit of 8 mmol/L per 24 hours in high-risk patients, and 10 to 12 mmol/L in others with chronic severe hyponatremia.
2. Use small fixed boluses of 3% saline for symptomatic patients. Aim to raise sodium about 4 to 6 mmol/L promptly rather than running an open-ended infusion; bolus dosing performed at least as safely as infusion in the only randomized trial.
3. Monitor serum sodium frequently, every 2 to 6 hours during active correction. Watch urine output closely, because a sudden brisk diuresis signals impending overshoot before the sodium has climbed.
4. Use desmopressin to control the rate. Give it proactively in the highest-risk patients or reactively at the first sign of aquaresis, and re-lower with 5% dextrose if the ceiling is crossed.
5. Individualize, and weigh the current debate. Rigidly minimizing the correction rate in patients without classic ODS risk factors is not clearly beneficial and may delay needed correction; match caution to the patient’s actual risk.

Evidence Grade and Bottom Line

• The dual risk is real: both undercorrection and overcorrection cause harm, and osmotic demyelination remains a serious, largely preventable complication.
• Established practice — capping the 24-hour rise near 8 to 10 mmol/L, giving hypertonic saline as small boluses, monitoring closely, and using desmopressin to brake — is well supported and safe.
• The strict lower limits are now questioned by observational data linking slow correction to higher mortality, but confounding prevents a firm causal claim, and guideline authors advise staying the course, especially in high-risk patients.
• Best current practice individualizes the target to each patient’s ODS risk rather than applying one rigid ceiling to everyone.

Article Information and References

1. Ayus JC, Moritz ML, Fuentes NA, et al. Correction rates and clinical outcomes in hospitalized adults with severe hyponatremia: a systematic review and meta-analysis. JAMA Intern Med. 2025;185(1):38–51. DOI: https://doi.org/10.1001/jamainternmed.2024.5981
2. Suppadungsuk S, Krisanapan P, Kazeminia S, et al. Hyponatremia correction and osmotic demyelination syndrome risk: a systematic review and meta-analysis. Kidney Med. 2025;7(3):100953. DOI: https://doi.org/10.1016/j.xkme.2024.100953
3. See XY, Chang YC, Peng CY, et al. Rate of sodium correction and osmotic demyelination syndrome in severe hyponatremia: a meta-analysis. J Crit Care Med (Targu Mures). 2024;10(3):209–212. DOI: https://doi.org/10.2478/jccm-2024-0030
4. Woodfine JD, van Walraven C. Criteria for hyponatremic overcorrection: systematic review and cohort study of emergently ill patients. J Gen Intern Med. 2020;35(1):315–321. DOI: https://doi.org/10.1007/s11606-019-05286-y
5. Baek SH, Jo YH, Ahn S, et al. Risk of overcorrection in rapid intermittent bolus vs slow continuous infusion therapies of hypertonic saline for patients with symptomatic hyponatremia: the SALSA randomized clinical trial. JAMA Intern Med. 2021;181(1):81–92. DOI: https://doi.org/10.1001/jamainternmed.2020.5519
6. George JC, Zafar W, Bucaloiu ID, Chang AR. Risk factors and outcomes of rapid correction of severe hyponatremia. Clin J Am Soc Nephrol. 2018;13(7):984–992. DOI: https://doi.org/10.2215/CJN.13061117
7. MacMillan TE, Shin S, Topf J, et al. Osmotic demyelination syndrome in patients hospitalized with hyponatremia. NEJM Evid. 2023;2(4):EVIDoa2200215. DOI: https://doi.org/10.1056/EVIDoa2200215
8. Seethapathy H, Zhao S, Ouyang T, et al. Severe hyponatremia correction, mortality, and central pontine myelinolysis. NEJM Evid. 2023;2(10):EVIDoa2300107. DOI: https://doi.org/10.1056/EVIDoa2300107
9. Sterns RH, Rondon-Berrios H, Adrogué HJ, et al; PRONATREOUS Investigators. Treatment guidelines for hyponatremia: stay the course. Clin J Am Soc Nephrol. 2024;19(1):129–135. DOI: https://doi.org/10.2215/CJN.0000000000000244
10. Verbalis JG, Goldsmith SR, Greenberg A, et al. Diagnosis, evaluation, and treatment of hyponatremia: expert panel recommendations. Am J Med. 2013;126(10 Suppl 1):S1–S42. DOI: https://doi.org/10.1016/j.amjmed.2013.07.006
11. Spasovski G, Vanholder R, Allolio B, et al; Hyponatraemia Guideline Development Group. Clinical practice guideline on diagnosis and treatment of hyponatraemia. Eur J Endocrinol. 2014;170(3):G1–G47. DOI: https://doi.org/10.1530/EJE-13-1020
12. Yang H, Yoon S, Kim EJ, et al. Risk factors for overcorrection of severe hyponatremia: a post hoc analysis of the SALSA trial. Kidney Res Clin Pract. 2022;41(3):298–309. DOI: https://doi.org/10.23876/j.krcp.21.180
13. Waikar SS, Mount DB, Curhan GC. Mortality after hospitalization with mild, moderate, and severe hyponatremia. Am J Med. 2009;122(9):857–865. DOI: https://doi.org/10.1016/j.amjmed.2009.01.027